Medical Information Notice: This article is for general education only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified clinician for your personal situation.

Prostate cancer is a malignant tumor that develops from cells in the prostate gland, a walnut-sized organ located below the bladder that produces seminal fluid. While it often grows slowly, more aggressive forms do exist. Many men die with prostate cancer rather than as a direct result of it.
1. Symptoms (Often absent in early stages; appear as cancer grows or spreads):

  • Urinary Problems: Weak/interrupted flow, frequent urination (especially at night), difficulty starting/stopping, pain/burning, blood in urine/semen.
  • Erectile Dysfunction (ED): Difficulty getting/maintaining an erection.
  • Pain: In the back, hips, pelvis (if spread to bones).
  • Advanced Disease: Leg swelling (lymphedema), weight loss, fatigue, bone fractures

2. Risk Factors:

  • Age: Risk increases dramatically after 50. Most cases are diagnosed in men over 65.
  • Race/Ethnicity: Higher incidence and mortality in Black men compared to White, Asian, or Hispanic men. The reasons are complex (genetic, social, and access).
  • Family History: Having a father or brother with prostate cancer doubles the risk. Risk is higher with early-onset relatives or multiple affected relatives.
  • Inherited Gene Mutations: Mutations in genes like BRCA1, BRCA2, HOXB13, Lynch syndrome genes increase risk.
  • Geography: More common in North America, Northwestern Europe, Australia, and the Caribbean than in Asia or Africa (lifestyle/environment likely play roles).
  • Diet: Potential links to diets high in red/processed meats, high-fat dairy, and low in fruits/vegetables. Obesity may increase the risk of aggressive forms.
    3. Screening & Early Detection (Controversial - involves weighing benefits vs. harms):
  • Prostate-Specific Antigen (PSA) Blood Test: Measures PSA protein produced by prostate cells. Elevated levels can indicate cancer, but also occur in BPH (benign enlargement), prostatitis, or after procedures. Not a perfect test.
  • Digital Rectal Exam (DRE): The Doctor feels the prostate for lumps/hardness through the rectum.
  • Guidelines (Vary by Organization - Shared Decision-Making is Key):
    • USPSTF (2023 Draft): Recommends discussing PSA screening:
      • Ages 55-69: Individualized decision based on risk factors/preferences.
      • Age 70+: Routine screening not recommended.
    • American Cancer Society: Discuss screening starting at:
      • Age 50 for average-risk men with >10-15 years of life expectancy.
      • Age 45 for high-risk men (Black men, family history before 65).
      • Age 40 for very high-risk men (multiple relatives with early-onset).
  • Harms of Screening: Overdiagnosis (finding slow-growing cancers that wouldn't cause harm), Overtreatment (side effects from treating insignificant cancers), False positives (leading to unnecessary biopsies).
    4. Diagnosis:
  • Abnormal PSA/DRE: Triggers further investigation.
  • Multiparametric MRI (mpMRI): Increasingly used before biopsy to identify suspicious areas and guide biopsy.
  • Prostate Biopsy: Core needle biopsy guided by ultrasound (often now fused with MRI images). Tissue is examined under a microscope.
  • Pathology Report: Includes:
    • Gleason Score/Grade Group: Measures how aggressive the cancer looks (how abnormal the cells/tissue patterns are). Higher score/group = more aggressive.
    • TNM Staging: Describes tumor size/location (T), lymph node involvement (N), metastasis (M).
    • PSA Level: At diagnosis.
  • Genomic Testing: On biopsy tissue (e.g., Decipher, Oncotype DX GPS) may be used for some localized cancers to better predict aggressiveness and guide treatment decisions.
    5. Treatment (Highly personalized based on stage, grade, PSA, age, health, side effect concerns):
  • Active Surveillance: For low-risk, very low-risk, or some favorable intermediate-risk cancers. Close monitoring (PSA, DRE, repeat biopsies, mpMRI) with treatment if signs of progression. Avoids immediate treatment side effects.
  • Watchful Waiting: Less intensive monitoring than AS; for older men/less healthy; aims to manage symptoms if they develop, not necessarily cure.
  • Surgery:
    • Radical Prostatectomy: Removal of the entire prostate and seminal vesicles +/- lymph nodes. Approaches: Open, Laparoscopic, Robot-assisted (common).
    • Side Effects: Erectile dysfunction, urinary incontinence (usually improves over months), infertility.
  • Radiation Therapy:
    • External Beam Radiation Therapy (EBRT): Delivered over weeks (IMRT, IGRT, SBRT). Often combined with ADT for intermediate/high risk.
    • Brachytherapy: Radioactive seeds implanted directly into the prostate (low-dose rate - LDR) or temporary high-dose catheters (high-dose rate - HDR). Often for low/intermediate risk.
    • Side Effects: Urinary/rectal irritation, ED (often delayed), fatigue.
  • Focal Therapy: Experimental techniques (HIFU, Cryotherapy, Laser) targeting only the tumor within the prostate. Not standard; long-term data limited.
  • Androgen Deprivation Therapy (ADT) / Hormone Therapy:
    • LHRH Agonists/Antagonists: Stop testicles from making testosterone (e.g., Leuprolide, Goserelin, Degarelix).
    • Anti-Androgens: Block testosterone from reaching cancer cells (e.g., Bicalutamide, Enzalutamide, Apalutamide, Darolutamide).
    • CYP17 Inhibitors: Block testosterone production throughout body (e.g., Abiraterone).
    • Used for advanced/metastatic disease, or combined with radiation for high-risk localized disease.
    • Side Effects: Hot flashes, loss of libido, ED, fatigue, bone thinning, muscle loss, weight gain, mood changes, increased CV risk.
  • Chemotherapy: Used for metastatic castration-resistant prostate cancer (mCRPC) that stops responding to ADT (e.g., Docetaxel, Cabazitaxel).
  • Immunotherapy:
    • Sipuleucel-T (Provenge): Vaccine for asymptomatic/minimally symptomatic mCRPC.
    • Pembrolizumab: For rare tumors with specific genetic features (MSI-H/dMMR).
  • Targeted Therapy:
    • PARP Inhibitors (Olaparib, Rucaparib): For mCRPC with specific DNA repair gene mutations (e.g., BRCA1/2).
    • Radium-223 (Xofigo): Targets bone metastases with radiation.
  • Radiopharmaceuticals:
    • Lutetium Lu 177 vipivotide tetraxetan (Pluvicto): Targets PSMA-positive mCRPC.
    • Radium-223: See above.
  • Bone Health Management: Bisphosphonates (Zoledronic acid) or Denosumab to prevent fractures in men on ADT or with bone mets.
    7. Prevention (No guaranteed way, but may reduce risk):
  • Healthy Diet: Rich in fruits, vegetables (especially cruciferous), whole grains; limit red/processed meats, high-fat dairy.
  • Healthy Weight: Maintain a healthy BMI.
  • Regular Exercise.
  • Discuss Risks: With doctor, especially if high-risk (family history, Black race). Make informed decisions about screening.
    8. Prognosis (Generally very good if caught early):
  • Localized/Low Risk: Near 100% 5-year survival. Often curable.
  • Regional Spread: High 5-year survival (>95%), but higher chance of recurrence.
  • Distant Metastases (Stage IV): 5-year survival is approximately 32% (US data), though improving with newer therapies. Treatable but generally not curable; focus shifts to managing disease and quality of life.
  • Key Factors: Stage at diagnosis, Gleason Score/Grade Group, PSA level, response to treatment.

Frequently Asked Questions (FAQ)

Q1: What is the PSA test and is it reliable?
The Prostate-Specific Antigen (PSA) test measures a protein produced by both normal and cancerous prostate cells. An elevated PSA can indicate prostate cancer but also occurs with benign prostatic hyperplasia (BPH), prostatitis, or after procedures. It is not a perfect test — it can both miss cancers and lead to unnecessary biopsies. Shared decision-making with a doctor is essential when considering PSA screening.

Q2: What is a Gleason score and what does it mean?
The Gleason score (or Grade Group) is assigned by a pathologist after examining prostate biopsy tissue under a microscope. It reflects how abnormal the cancer cells look compared to normal cells. A higher score/group indicates a more aggressive cancer that is more likely to grow and spread quickly. The score is critical for guiding treatment decisions.

Q3: What is active surveillance and who is it for?
Active surveillance involves closely monitoring low-risk or very-low-risk prostate cancer without immediate treatment. It includes regular PSA tests, digital rectal exams, repeat biopsies, and MRI scans. Treatment is initiated only if signs of progression appear. This approach avoids the side effects of immediate treatment for cancers unlikely to cause harm in a patient's lifetime.

Q4: What are the main side effects of prostate cancer treatment?
Side effects vary by treatment. Surgery (radical prostatectomy) carries risks of erectile dysfunction and urinary incontinence. Radiation therapy can cause urinary irritation, rectal problems, and delayed erectile dysfunction. Androgen deprivation therapy (ADT/hormone therapy) causes hot flashes, loss of libido, bone thinning, fatigue, and cardiovascular risks.

Q5: Why are Black men at higher risk of prostate cancer?
Black men have the highest incidence and mortality rates from prostate cancer in the US, about 70% higher than White men. The reasons are multifactorial, involving genetic factors, potentially biological differences in tumor behavior, socioeconomic disparities, and inequities in access to healthcare and early screening. Major cancer organizations recommend offering screening discussions to Black men starting at age 40–45.

Q6: What does androgen deprivation therapy (ADT) do?
ADT (also called hormone therapy) reduces testosterone levels, which fuels prostate cancer growth. It is used for advanced or metastatic prostate cancer, or combined with radiation for high-risk localized disease. While effective, it is not curative for advanced disease, and cancer often eventually becomes "castration-resistant" over time.

Q7: What is the prognosis for prostate cancer?
Prostate cancer has one of the best overall prognoses of any cancer. Localized or regional prostate cancer has near-100% and >95% 5-year survival rates, respectively. Even metastatic (Stage IV) prostate cancer has a 5-year survival of approximately 32%, which is improving with newer therapies. Many men diagnosed with low-risk prostate cancer live for decades without significant harm from the disease.

Medical Disclaimer

MediPulse publishes this content for patient education. It may not reflect the latest guideline changes in every jurisdiction. Do not delay seeking care because of something you read here.